The following are the requirements for the medical certification of aircrew, including guidance material issued by the UK CAA Medical Department in relation to the Oncology.
(a) Before further consideration is given to their application, applicants with primary or secondary malignant disease shall undergo satisfactory oncological evaluation. Such applicants for a class 1 medical certificate shall be referred to the medical assessor of the licensing authority. Such applicants for a class 2 medical certificate shall be assessed in consultation with the medical assessor of the licensing authority.
(b) Applicants with a documented medical history or clinical diagnosis of an intracerebral malignant tumour shall be assessed as unfit.
CLASS 1 - AMC1 MED.B.090
(a) Applicants who have been diagnosed with a malignant disease may be assessed as fit provided that:
(1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety;
(2) time appropriate to the type of tumour and primary treatment has elapsed;
(3) the risk of inflight incapacitation from a recurrence or metastasis is sufficiently low;
(4) there is no evidence of short or long-term sequelae from treatment. Special attention should be paid to applicants who have received anthracycline chemotherapy;
(5) satisfactory oncology follow-up reports are provided to the medical assessor of the licensing authority.
(b) An OML should be applied as appropriate.
(c) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.
(d) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is regular follow-up.
On reporting a diagnosis of malignancy, applicants should be assessed as unfit.
Recertification can be considered following receipt of a satisfactory specialist report with the information in the
15 point Oncology Request table (PDF).
Note 1: All Class 1 applicants shall be referred to the AMS.
1. Recertification a minimum of 6 weeks after the last dose of chemotherapy, subject to satisfactory blood tests results (FBC, U&Es, LFTs, relevant tumour markers as a minimum).
2. If any complications from treatment, need full recovery. If unresolved, may require appropriate specialist assessment, e.g. neuropathy may require a specialist neurology assessment. 3. Class 1 pilots who have had anthracycline (e.g. doxorubicin, adriamycin, daunorubicin) require cardiological assessment in accordance with the anthracycline (PDF) flow chart.
(3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;
(4) there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety;
(5) arrangements for an oncological follow-up have been made for an appropriate period of time.
(b) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.
(c) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up.
1. Recertification a minimum of 4 weeks after the last dose of radiotherapy.
2. If any complications from treatment, need full recovery. If unresolved, appropriate specialist assessment required e.g. radiation pneumonitis/pulmonary fibrosis requires a specialist respiratory assessment.
As a guide, minimum post-operative grounding periods:
Minor e.g. skin lesion 1 Week
Intermediate e.g. prostatectomy (TURP) 6 weeks
Major e.g. hemicolectomy 3 months
Metastatic disease is disqualifying for Class 1 and Class 2 certification.
In exceptional cases, Class 2 OSL may be considered by CAA Medical only.
Incapacitation risks are based on: 1) Risk of a recurrence 2) Site of the recurrence 3) Risk of a recurrence at that site leading to an incapacitation.
CAA Oncology Certification Charts (PDF) have been developed based on these medical incapacitation risks: 2-5% per annum Class 2 OSL ≤ 1% per annum Class 1 OML & Class 2 unrestricted 0.1% per annum Class 1 Unrestricted
All Class 1 lymphoid malignancies must be referred to the CAA.
The above guidance is also available in Ernsting’s Textbook of Aviation Medicine 5th Edition, Chapter 28, Malignant Disease.
UK CAA Guidance on certification after Prostate Cancer (PDF)
RT @transportgovuk: This time last year we launched the Women in Aviation and Aerospace Charter - a commitment to build a more balanced and…
22 hours ago
To mark one year since the publication of the Women in Aviation and Aerospace Charter, we have spoken to Kirsten Ri… https://t.co/XDrAkIeMdy
In case you missed it, last week the @UK_CAA published its report on the disability access of the UK's largest airp… https://t.co/YOm5YhOcit
4 days ago
Read all @UK_CAA
UK Civil Aviation Authority reports on disabled access at UK airports
11 July, 2019
UK Civil Aviation Authority appoints new Non-Executive Director
5 July, 2019
Passengers urged to read Terms and Conditions when booking flights
24 June, 2019
Read all News
Our unmanned aircraft systems unit
5 June, 2019
Inspecting commercial drone operators
29 March, 2019
World ATM Congress….or should that be World UTM Congress?
22 March, 2019
Read All Blogs